FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004167584> ?p ?o ?g. }

• W2004167584 endingPage "1291" @default.
• W2004167584 startingPage "1280" @default.
• W2004167584 abstract "Changes in the pharmacokinetics of antiarrhythmic agents may be anticipated in patients with congestive heart failure (CHF), although the magnitude or direction of change is not always predictable. Factors complicating antiarrhythmic therapy in patients with CHF include both physiologic changes resulting from the disease state and unwanted effects of drug therapy for CHF. The volume of distribution is often significantly decreased (by as much as 50%) and loading doses should be reduced proportionately. Decreased blood flow to the liver and kidneys and decreased hepatic drug-metabolizing activity serve to diminish drug clearance. In some cases, simultaneous decreases in volume of distribution and clearance may result in little, if any, change in elimination half-life, despite higher plasma concentrations. Conversely, the elimination half-life of antiarrhythmic agents may be doubled in patients with CHF, necessitating a reduction in dosage. In the latter case, the time needed to reach steady state is lengthened, so that premature escalation of dosage may lead to excessive drug accmulation. In terms of their pharmacodynamics, most antiarrhythmic agents have a degree of negative inotropic effect at some concentration, and patients with reduced myocardial reserve are especially vuinerabie to these effects. Some of the newer agents (such as tocainide, mexiletine, and encainide) appear to cause only minimal myocardial depression. Potential complications during therapy with all antiarrhythmic agents that are of special concern in patients with CHF include diuretic-induced hypokalemia, proarrhythmia, and possible interactions with cardiac glycosides and other drugs. Therapy for patients with CHF should be initiated with low doses of the agent selected, and the dosage carefully titrated while the patient is monitored, to confirm both efficacy and the absence of adverse effects. During subsequent outpatient therapy the patient should be carefully observed for signs of unexpected reactions, toxicity, or electrolyte imbalance." @default.
• W2004167584 created "2016-06-24" @default.
• W2004167584 creator A5065408128 @default.
• W2004167584 date "1987-11-01" @default.
• W2004167584 modified "2023-09-27" @default.
• W2004167584 title "Pharmacokinetics and pharmacodynamics of antiarrhythmic agents in patients with congestive heart failure" @default.
• W2004167584 cites W1676675240 @default.
• W2004167584 cites W1963663695 @default.
• W2004167584 cites W1967309590 @default.
• W2004167584 cites W1968060160 @default.
• W2004167584 cites W1977585659 @default.
• W2004167584 cites W1979205209 @default.
• W2004167584 cites W1980463860 @default.
• W2004167584 cites W1985888466 @default.
• W2004167584 cites W1990456563 @default.
• W2004167584 cites W1990998921 @default.
• W2004167584 cites W1992747592 @default.
• W2004167584 cites W1993205403 @default.
• W2004167584 cites W1996437349 @default.
• W2004167584 cites W1997840244 @default.
• W2004167584 cites W1999223868 @default.
• W2004167584 cites W2005604952 @default.
• W2004167584 cites W2010074722 @default.
• W2004167584 cites W2010904013 @default.
• W2004167584 cites W2011476261 @default.
• W2004167584 cites W2014933258 @default.
• W2004167584 cites W2016460554 @default.
• W2004167584 cites W2017381092 @default.
• W2004167584 cites W2035105123 @default.
• W2004167584 cites W2035335006 @default.
• W2004167584 cites W2037887440 @default.
• W2004167584 cites W2045158921 @default.
• W2004167584 cites W2048980662 @default.
• W2004167584 cites W2050411807 @default.
• W2004167584 cites W2050559333 @default.
• W2004167584 cites W2051723724 @default.
• W2004167584 cites W2052420549 @default.
• W2004167584 cites W2052629510 @default.
• W2004167584 cites W2053149232 @default.
• W2004167584 cites W2059178292 @default.
• W2004167584 cites W2059347897 @default.
• W2004167584 cites W2060366212 @default.
• W2004167584 cites W2065254412 @default.
• W2004167584 cites W2065417034 @default.
• W2004167584 cites W2069765041 @default.
• W2004167584 cites W2070849869 @default.
• W2004167584 cites W2071412839 @default.
• W2004167584 cites W2071587920 @default.
• W2004167584 cites W2080834065 @default.
• W2004167584 cites W2083397218 @default.
• W2004167584 cites W2087208771 @default.
• W2004167584 cites W2088528141 @default.
• W2004167584 cites W2090543052 @default.
• W2004167584 cites W2094892482 @default.
• W2004167584 cites W2111879726 @default.
• W2004167584 cites W2112848028 @default.
• W2004167584 cites W2113745107 @default.
• W2004167584 cites W2130784560 @default.
• W2004167584 cites W2140554968 @default.
• W2004167584 cites W2141151888 @default.
• W2004167584 cites W2168818115 @default.
• W2004167584 cites W2170908814 @default.
• W2004167584 cites W2394504483 @default.
• W2004167584 cites W4213205077 @default.
• W2004167584 cites W4235788903 @default.
• W2004167584 cites W5544023 @default.
• W2004167584 doi "https://doi.org/10.1016/0002-8703(87)90217-1" @default.
• W2004167584 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3314444" @default.
• W2004167584 hasPublicationYear "1987" @default.
• W2004167584 type Work @default.
• W2004167584 sameAs 2004167584 @default.
• W2004167584 citedByCount "37" @default.
• W2004167584 countsByYear W20041675842012 @default.
• W2004167584 countsByYear W20041675842013 @default.
• W2004167584 countsByYear W20041675842014 @default.
• W2004167584 countsByYear W20041675842015 @default.
• W2004167584 countsByYear W20041675842018 @default.
• W2004167584 countsByYear W20041675842020 @default.
• W2004167584 countsByYear W20041675842022 @default.
• W2004167584 countsByYear W20041675842023 @default.
• W2004167584 crossrefType "journal-article" @default.
• W2004167584 hasAuthorship W2004167584A5065408128 @default.
• W2004167584 hasConcept C111113717 @default.
• W2004167584 hasConcept C112705442 @default.
• W2004167584 hasConcept C126322002 @default.
• W2004167584 hasConcept C139254425 @default.
• W2004167584 hasConcept C155710745 @default.
• W2004167584 hasConcept C164705383 @default.
• W2004167584 hasConcept C2777008848 @default.
• W2004167584 hasConcept C2777561782 @default.
• W2004167584 hasConcept C2778198053 @default.
• W2004167584 hasConcept C2778242168 @default.
• W2004167584 hasConcept C2780035454 @default.
• W2004167584 hasConcept C71924100 @default.
• W2004167584 hasConcept C98274493 @default.
• W2004167584 hasConceptScore W2004167584C111113717 @default.
• W2004167584 hasConceptScore W2004167584C112705442 @default.
• W2004167584 hasConceptScore W2004167584C126322002 @default.

• next